Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Metro Bank Down Amid Mortgage Competition

Wed, 24th Oct 2018 10:43

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - WINNERS----------Barclays, up 0.9%. The bank reported a rise in third quarter profit but year-to-date profit remained lower, dragged by litigation costs and conducts charges experienced earlier in the year.For the three months ended September, Barclays pretax profit increased sharply to GBP1.46 billion from GBP1.11 billion in the third quarter of 2017. The improvement was led by Barclays investment bank, which helped the Barclays International division to a 30% rise in profit. The group raised its third quarter dividend to 2.5 pence from 1.0p paid a year before. Barclays reiterated its intention to pay a total dividend of 6.5p for 2018.----------International Consolidated Airlines Group up 1.5%. Deutsche Bank raised is rating on European Airlines sector to Overweight from Underweight. easyJet was up 0.5%.----------FTSE 100 - LOSERS----------Fresnillo, down 2.7%. The gold miner revised its annual production guidance after having mixed results in the third quarter. The company said gold production in the three months to the end of September 30 declined by 3.5% to 225,000 ounces, while silver production increased by 6.3% year-on-year to 15.5 million ounces. However, Fresnillo said third-quarter silver production was not as high as anticipated and reduced its annual guidance for silver output to between 62.0 million and 64.5 million ounces from 64.5 million to 67.5 million ounces estimated earlier. Fresnillo now expects to produce between 920,000 and 940,000 ounces of gold in the full year, up from 900,000 to 930,000 ounces guided previously. Fellow gold miner Randgold Resources was down 1.7%.----------FTSE 250 - WINNERS----------Equiniti, up 0.6%. The payments services provider won two pension administration contracts in the UK nuclear sector. Under the terms of the contracts, Equiniti's pension division, EQPaymaster, will support virtually all employees and former employees engaged in the UK nuclear industry. The contracts are for the UK Atomic Energy Authority and for the Combined Nuclear Pension Plan, covering 60,000 members in total.----------FTSE 250 - LOSERS----------Metro Bank, down 7.9%. The challenger bank said it is experiencing continued competition in residential mortgages resulting in "slowed margin progress". Net interest margin fell by 15 basis points to 1.82%. More positively, Metro Bank reported lending growth of 52% in the first nine months to GBP13.12 billion from GBP8.61 billion, with commercial loans up 43% to GBP4.17 billion and residential mortgages up 59% to GBP8.72 billion. Underlying pretax profit multiplied to GBP39.2 million from GBP13.2 million, while statutory pretax profit jumped to GBP25.1 million from GBP7.8 million. At the end of the period, the bank's assets stood at GBP20.57 billion, up 41% year-on-year, while its loan to deposit ratio grew to 89% from 80%. Its Common Equity Tier 1 Capital ratio remained robust at 15.7% as at September-end. ----------Stobart Group, down 5.4%. The infrastructure & support services company swung to a loss in the first half of its financial year, despite a 21% increase in revenue. For the six months to August 31, Stobart reported a pretax loss of GBP18.8 million compared with a GBP111.6 million profit in the same period a year ago. Interim revenue increased to GBP151.3 million from GBP124.6 million year-on-year. The company's profit was hurt by the lack of income generated by the sale of its 49% interest in the parent of Eddie Stobart, Greenwhitestar Holding Co 1, which resulted in a GBP123.8 million profit figuring in its interim balance sheet a year ago. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Photo-Me International, up 10%. The photo-booth operator maintained its annual guidance following the completion of restructuring of its Japanese unit. Photo-Me said it removed unprofitable machines and installed new ones with a "significantly" lower production cost. As a result, the company expects to have a 35% faster return on its Japanese investment. Photo-Me said its deployment of encrypted photo ID upload technology has "continued to progress well", with 2,700 photo booths in the UK now enabled for UK passport renewals. The company is now targeting the deployment of 4,000 enabled photo booths by the end of December.----------OTHER MAIN MARKET AND AIM - LOSERS----------Yu Group, down 83%. The gas & electricity supplier said it expects a GBP10 million reduction in profit, which will send it to a loss, after discovering areas of concern in a performance review. One of the areas of concern for the group was the recognition of historic accrued income, which totalled GBP4.2 million for 2017 and GBP4.3 million for the six months to June. The level of trade debtors held also caused concern to the group, as if found that the level of non-payment being experienced is "significantly above that which has been previously provided for". Looking ahead, despite being "extremely disappointed" to reveal the profitability drop, Yu said it expects to achieve a profit in 2019. ----------Scancell Holdings, down 15%. The biopharmaceutical company said the US Food & Drug Administration has asked for further information on its SCIB1 product's proposed trial. Scancell applied for an investigational new drug application to the FDA for SCIB1, which will be trialled in combination with pembrolizumab in patients with advanced melanoma. The trial is being carried out alongside Ichor Medical Systems Inc's TriGrid electroporation delivery system, and it is further information on this that the US regulator has asked for. The system, Scancell said, has been used on the previous SCIB1 phase 1/2 stud, which had favourable results.----------
More News
20 Nov 2019 10:01

Scancell To Receive New European Patent For Moditope Product

Scancell To Receive New European Patent For Moditope Product

Read more
23 Oct 2019 10:48

Scancell Hires Former Genkyotex Boss Ursula Ney As Non-Executive

Scancell Hires Former Genkyotex Boss Ursula Ney As Non-Executive

Read more
5 Sep 2019 16:03

UK Shareholder Meetings Calendar - Next 7 Days

Friday 6 SeptemberMySale Group (re share placing)Berkeley GroupGreene 9 African Oil & 10 11 Design

Read more
4 Sep 2019 08:58

Scancell signs collaboration agreement with antibody technology company

(Sharecast News) - Cancer treatment developer Scancell has inked its first collaboration agreement with a "leading" antibody technology company for its new platform technology, AvidiMab.

Read more
20 Aug 2019 10:59

Scancell losses deepen as it presses on with development

(Sharecast News) - Novel immunotherapies developer Scancell Holdings reported a deeper operating loss in its final results on Tuesday, to £6.73m compared to £4.91m in the 2018 financial year.

Read more
20 Aug 2019 10:59

Scancell Annual Loss Widens Amid Product Pipeline Development

(Alliance News) - Immunotherapy firm Scancell Holdings PLC on Tuesday said its loss widened on higher development costs, while it is making strong progress on advancing its the 12 months to the of

Read more
19 Aug 2019 09:33

Scancell to begin SCIB1 UK trial as FDA issues linger in US

(Sharecast News) - Immunotherapy developer Scancell announced the initiation of and further updates to the 'SCIB1' phase 2 trial in patients with metastatic melanoma also receiving the checkpoint inhibitor 'pembrolizumab' (Keytruda) on Monday.

Read more
13 Aug 2019 15:58

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 14 AugustĀ AvastHalf Year ResultsLookersHalf Year BeattyHalf Year Year

Read more
1 Jul 2019 14:42

Scancell Progresses Trials In "Busy And Productive" Six Months

(Alliance News) - Scancell Holdings PLC said on Monday it has been a "busy and productive" six months for the company.The company said that active patient recruitment for the two

Read more
18 Jun 2019 14:40

Scancell Appoints Vulpes Investment Management Co-Founder To Board

(Alliance News) - Scancell Holdings PLC on Tuesday said it has appointed Vulpes Investment Management Co-Founder & Portfolio Manager Martin Diggle to its board.Diggle joins the cancer a

Read more
13 Jun 2019 13:48

Scancell Shares Jump 30% As Vulpes Invests GBP4 Million (ALLISS)

(Alliance News) - Scancell Holdings PLC's shares soared Thursday as it received GBP3.9 million from a new investor.Scancell shares were up 31% in afternoon trade at a price of 7.00 Life

Read more
21 May 2019 13:25

N4 Pharma Appoints John Chiplin as Non-Executive Chairman

LONDON (Alliance News) - N4 Pharma PLC on Tuesday said it appointed John Chiplin as non-executive chair of the company with immediate effect.Furthermore, the pharmaceutical firm appointed a

Read more
20 May 2019 11:03

Scancell partnership with Cancer Research moves closer to clinic

(Sharecast News) - Immunotherapy developer Scancell Holdings updated the market on its clinical development partnership with Cancer Research UK for the development of the ;ImmunoBody' vaccine, SCIB2, as a potential treatment for patients with solid tumours, including non-small cell lung cancer (NSCLC), on Monday.

Read more
20 May 2019 11:02

Scancell Says Cancer Vaccine SCIB2 Will Be Given Using New Formulation

LONDON (Alliance News) - Scancell Holdings PLC said Monday cancer vaccine SCIB2 is to be administered using a new nanoparticle formulation in an early stage trial.Shares in Scancell were up

Read more
10 May 2019 10:49

Scancell Creates Advisory Board And Prepares For Drug Trials

LONDON (Alliance News) - Scancell Holdings PLC on Friday said it has established a clinical advisory board and has begun manufacturing and toxicity testing on its tumour drug in immunotherapy were

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.